Fulcrum Therapeutics Inc. (NASDAQ:FULC) Q2 2020 Results Conference Call August 11, 2020 8:00 AM ET
Company Participants
Christi Waarich - Director, Corporate Communications & IR
Robert Gould - CEO, President & Director
Diego Cadavid - SVP of Clinical Development
Owen Wallace - Chief Scientific Officer
Bryan Stuart - Chief Operating Officer
Conference Call Participants
Joseph Schwartz - SVB Leerink
Dae Gon Ha - BTIG
Tazeen Ahmad - Bank of America
Ted Tenthoff - Piper Sandler
Matthew Harrison - Morgan Stanley
Operator
Good morning and welcome to the Fulcrum Therapeutics Conference Call. [Operator Instructions].
I'd now like to turn the call over to Christi Waarich, Director of Investor Relations and Corporate Communications at Fulcrum. Please proceed.
Christi Waarich
Thank you, Anthony. Good morning, and thank you for joining us. Earlier today, we issued two press releases: one, outlining the results of our interim analysis for losmapimod in FSHD; and another outlining our recent corporate progress and financial results for the second quarter of 2020. You can find both of these in the Investor Relations section of our website at fulcrumtx.com.
Please be reminded that remarks made during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about our future expectations and plans, clinical development time lines and financial projections. While these forward-looking statements represent our views as of today, they should not be relied upon as representing our views in the future. We may update these statements in the future, but we are not taking on an obligation to do so. Please refer to our most recent filings with the Securities and Exchange Commission for a discussion of certain risks and uncertainties associated with our business.
With me on today's call are Robert Gould, President and Chief Executive Officer; Diego
- Read more current FULC analysis and news
- View all earnings call transcripts